Drug intelligence / Profile preview

5,6-dihydro-5-azacytidine

Development stage: Unknown
Modality: Small Molecules

Overview

5,6-dihydro-5-azacytidine (DHAC) is a synthetic nucleoside analogue and a hydrolytically stable congener of 5‑azacytidine. It acts as an inhibitor of DNA methyltransferase enzymes and induces DNA hypomethylation. By interfering with abnormal DNA methylation patterns associated with genetic instability in tumor cells, DHAC may restore the expression of tumor-suppressor genes and exert antitumor activity. The compound has demonstrated cytostatic effects in vitro and was investigated in phase II clinical studies for several cancers including malignant melanoma and mesothelioma[1][3][5].

Other names: 5,6-dihydro-5-azacytidinedihydro-5-azacytidinedihydro5-azacytidinedihydro 5-azacytidine1,3,5-triazin-2(1h)-one, 4-amino-5,6-dihydro-1-.beta.-d-ribofuranosyl-

Targets

DNMT (DNA methyltransferase)

Beyond the preview

Go deeper on 5,6-dihydro-5-azacytidine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 5,6-dihydro-5-azacytidine.

Explore the full profile